GSK PLC closed 26.98% short of its 52-week high of £18.24, which the company reached on May 16th.

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across ...

GSK PLC closed 21.39% short of its 52-week high of £18.24, which the company reached on May 16th.

NEW YORK CITY, NY / ACCESS Newswire / April 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

NEW YORK CITY, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory uncertainties, GSK and Pfizer ... to be a biotech company right ...

The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official ...

GSK plc (NYSE:GSK) is a UK-based global biopharmaceutical company focused on the research, development, and manufacturing of medicines and vaccines. Its operations are structured around three core ...

GSK’s ViiV Healthcare has shared clinical data ... ViiV is racing on multiple fronts to meet the demand. The company used the 2025 Conference on Retroviruses and Opportunistic Infections ...